Cytoreduction with bridging therapy improves outcomes after CD19 CAR T-cell therapy in B-ALL with high disease burden

Blood Immunology & Cellular Therapy · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles